by Michael May | Jun 9, 2026
Fifteen years ago, regenerative medicine in Canada stood at an inflection point. The science was world-class, the academic talent was undeniable, and the promise of cell and gene therapies was beginning to capture global attention. Yet there was a critical problem:...
by Sanat Khanna | May 12, 2026
Cell therapy manufacturing generates large volumes of process data – from sensors, bioreactors, quality controls and genomic assays. In many facilities, much of that data are collected for regulatory compliance rather than for process improvement – a pattern that...
by CCRM Australia | Oct 1, 2025
Silvio Tiziani, MBA, GAICD, is the CEO of CCRM Australia, leading efforts to bridge the gap between research and industry in regenerative medicine. With extensive experience across academia, health, and industry, he has successfully developed strategic partnerships,...
by Laya Kiani | Jul 30, 2025
In recent years, the field of cell and gene therapy (CGT) has garnered significant attention for its groundbreaking potential to treat previously untreatable diseases. This excitement, however, is offset by growing awareness of the environmental footprint of these...
by Anis Fahandej-Sadi | Jun 5, 2025
Cancer treatment has advanced dramatically, but a central challenge remains: the newest tools in our arsenal are shockingly expensive. CAR T-cell therapies exemplify this—they’re amazing at fighting blood cancers, but a single treatment costs upwards of...
Comments